Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Dec;33(6):2209-16.
doi: 10.1007/s13277-012-0482-4. Epub 2012 Aug 14.

Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma

Wen Zhang  1 , Nannan Guo, Changhai Yu, Hongwei Wang, Yiming Zhang, Hui Xia, Jiangqi Yu, Jiangyang Lu
Affiliations
Clinical Trial

Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma

Wen Zhang et al. Tumour Biol. 2012 Dec.

Abstract

About 80 % of lung cancers are carcinomas that are classified histologically as non-small-cell lung carcinoma (NSCLC) and targeted chemotherapy of this cancer is currently based on sensitivity of the primary tumor to specific drugs. The purpose of this study was to compare the levels of four serum markers of cancer and the levels of six molecular markers which are possibly associated with drug selection in the primary tumors and metastatic lymph nodes of 39 consecutive NSCLC patients who were admitted to a single institution in China. Serum markers of cancer (neuron-specific enolase, carcinoembryonic antigen (CEA), cancer antigen 125, cytokeratin fragment 21-1) were measured by an automated electrochemiluminescence system and molecular markers (multidrug resistance protein 1, LDL receptor-related protein, ribonucleotide reductase M1, epidermal growth factor receptor, excision repair cross-complementing gene 1, and breast cancer 1) were measured by immunohistochemistry of the primary tumors and metastatic lymph nodes. The results indicate that the serum level of CEA was higher in NSCLC patients with adenocarcinoma relative to those with squamous cell carcinoma, but no significant differences in the other serum markers. Expression of excision repair cross-complementing gene 1 was significantly different in the primary tumors and metastatic sites of NSCLC patients with adenocarcinoma, but there were no other significant differences. This study provides an initial step toward the development of individualized chemotherapy of NSCLC based on measurement of molecular markers in the primary tumors and metastatic lymph nodes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Representative immunohistochemical staining results for LRP, RRM-1, EGFR, and ERCC-1, BRCA-1, and MDR-1 in a primary tumor (adenocarcinoma) and a metastatic lymph node (squamous cell carcinoma), ×400. Arrows indicate strong positive staining in the cytoplasma and the nucleus
Fig. 2
Fig. 2
Expression of serum tumor markers (NSE, CEA, CA 125, and CYFRA 21-1) in patients with different subtypes of NSCLC
Fig. 3
Fig. 3
The correlation between ERCC-1 and CEA levels in the primary tumor tissue (a) and the metatstatic lymph nodes (b)
See this image and copyright information in PMC

References

    1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594. - PMC - PubMed
    1. Zhang H, Cai B. The impact of tobacco on lung health in China. Respirology. 2003;8:17–21. doi: 10.1046/j.1440-1843.2003.00433.x. - DOI - PubMed
    1. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113–4120. doi: 10.1200/JCO.2010.31.8162. - DOI - PubMed
    1. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1:44–53. doi: 10.1158/2159-8274.CD-10-0010. - DOI - PMC - PubMed
    1. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299:1574–1587. doi: 10.1001/jama.299.13.1574. - DOI - PubMed

Publication types

MeSH terms